New Amsterdam Sciences

New Amsterdam Sciences (NAS) is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911, the company's lead compound, is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing, and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial and government markets, focusing specifically on mass casualty biodefense applications.